Transplantation therapies
Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
1. A dosage form for treating transplantation injury comprising an effective amount of Bryostatin-1, Bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil trans endothelial migration wherein said dosage form is for administration to a human or animal in need thereof; wherein said dosage form comprises saturated polyalkylene glycol glyceride; and wherein said effective amount in the organ is a plasma concentration is about 10 −7 M.
2. The dosage form of claim 1 wherein said dosage form is a solid oral dosage form.
3. The dosage form of claim 1 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol.
4. The dosage form of claim 3 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000 daltons.
5. The dosage form of claim 4 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600 daltons.
6. The dosage form of claim 2 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 1 to 30% by weight.
7. The dosage form of claim 2 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 10 to 20% by weight.
8. The dosage form of claim 2 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 2 to 25% by weight.
9. The dosage form of claim 1 wherein said dosage form is a pharmaceutical parenteral formulation.
10. The dosage form of claim 9 wherein said pharmaceutical parenteral formulation comprises polyalkylene glycol glyceride.
11. The dosage form of claim 9 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol.
12. The dosage form of claim 11 wherein said polyalkylene glycol is a polyethylene Glycol having a molecular weight of 1000 to 2000 daltons.
13. The dosage form of claim 12 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600 daltons.
14. The dosage form of claim 9 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.00005 to 0.5% by weight.
15. The dosage form of claim 9 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.001 to 0.1% by weight.
16. The dosage form of claim 9 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation in an amount of 0.01 to 0.1% by weight.
17. The dosage form of claim 9 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.0005 to 0.5% by weight.